Cargando…
Autoimmune Polyendocrinopathy Induced by an Antibody (KN046) That Simultaneously Inhibits PD-L1 and CTLA-4: A Case Report and Literature Review
Endocrine adverse reactions are one of the most common adverse reactions in the treatment of immune checkpoint inhibitors (ICIs), mainly involving the pituitary gland, pancreas, thyroid gland, adrenal gland and other glands, resulting in corresponding endocrine dysfunction. We report a 45-year-old m...
Autores principales: | Li, Min, Wu, Chenchen, Liu, Yan, Zhang, Ranran, Yang, Qingqing, Shi, Zhaoming, Sun, Weihua, Hu, Xiaolei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041354/ https://www.ncbi.nlm.nih.gov/pubmed/35494533 http://dx.doi.org/10.2147/DMSO.S353403 |
Ejemplares similares
-
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023) -
Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy
por: Ferré, Elise M. N., et al.
Publicado: (2021) -
Anti-Interferon Auto-Antibodies in Autoimmune Polyendocrinopathy Syndrome Type 1
por: Levin, Michael
Publicado: (2006) -
Autoimmune thyroiditis - track towards autoimmune polyendocrinopathy type III
por: Hodé, Annelie Kérékou, et al.
Publicado: (2021) -
Reversible adrenal insufficiency and heterophile antibodies in a case of autoimmune polyendocrinopathy syndrome
por: Kharb, Sandeep, et al.
Publicado: (2013)